Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 2:41 pm Purchase | 2024-12-31 | 13G | OncoCyte Corporation OCX | AWM Investment Company Inc. | 1,306,309 7.500% | 1,306,309 (New Position) | Filing History |
| 2025-02-10 8:46 pm Purchase | 2025-02-06 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 11,560,350 40.200% | 6,481,034 (+127.60%) | Filing History |
| 2024-12-27 9:58 pm Purchase | 2024-12-26 | 13G | OncoCyte Corporation OCX | SMITH PATRICK W | 1,773,903 10.500% | 215,466 (+13.83%) | Filing History |
| 2024-12-09 5:30 pm Purchase | 2024-12-05 | 13G | OncoCyte Corporation OCX | SMITH PATRICK W | 1,558,437 9.300% | 545,116 (+53.79%) | Filing History |
| 2024-11-14 1:26 pm Sale | 2024-11-14 | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 616,587 4.570% | -91,585 (-12.93%) | Filing History |
| 2024-10-24 12:13 pm Purchase | 2024-10-04 | 13G | OncoCyte Corporation OCX | BIO-RAD LABORATORIES INC. BIO | 1,510,944 8.970% | 310,835 (+25.90%) | Filing History |
| 2024-10-09 5:03 pm Purchase | 2024-10-02 | 13G | OncoCyte Corporation OCX | SMITH PATRICK W | 1,013,321 6.000% | 1,013,321 (New Position) | Filing History |
| 2024-04-22 1:30 pm Purchase | 2024-04-15 | 13G | OncoCyte Corporation OCX | BIO-RAD LABORATORIES INC. BIO | 1,200,109 8.990% | 1,200,109 (New Position) | Filing History |
| 2024-04-15 7:26 pm Purchase | 2024-04-11 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 5,079,316 37.600% | 5,079,316 (New Position) | Filing History |
| 2024-02-14 5:03 pm Sale | 2023-12-31 | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 708,172 8.450% | -123,919 (-14.89%) | Filing History |
| 2024-02-14 3:47 pm Purchase | 2023-12-31 | 13G | OncoCyte Corporation OCX | AWM Investment Company Inc. | 754,286 9.100% | 391,575 (+107.96%) | Filing History |
| 2023-04-14 4:31 pm Sale | 2023-04-14 | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 832,091 9.990% | -70,723 (-7.83%) | Filing History |
| 2023-04-07 10:38 am Purchase | 2023-04-03 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 2,856,559 33.300% | 1,345,914 (+89.10%) | Filing History |
| 2023-02-14 1:11 pm Unchanged | 2022-12-31 | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 902,814 15.220% | 0 (Unchanged) | Filing History |
| 2023-02-14 11:33 am Purchase | 2022-12-31 | 13G | OncoCyte Corporation OCX | PURA VIDA INVESTMENTS LLC | 902,814 15.220% | 291,616 (+47.71%) | Filing History |
| 2023-02-14 11:23 am Purchase | 2022-12-31 | 13G | OncoCyte Corporation OCX | AWM Investment Company Inc. | 362,711 6.100% | 362,711 (New Position) | Filing History |
| 2022-11-23 5:52 pm Purchase | 2022-11-11 | 13G | OncoCyte Corporation OCX | Norfield Capital LLC | 330,018 5.500% | 330,018 (New Position) | Filing History |
| 2022-07-28 5:06 pm Purchase | 2022-07-21 | 13D | OncoCyte Corporation OCX | BROADWOOD PARTNERS L.P. | 1,510,645 24.100% | 321,897 (+27.08%) | Filing History |
| 2022-05-09 3:23 pm Purchase | 2022-04-30 | 13G | OncoCyte Corporation OCX | BlackRock Inc. BLK | 250,261 4.200% | 604 (+0.24%) | Filing History |
| 2022-04-18 3:56 pm Purchase | 2022-04-18 | 13G | OncoCyte Corporation OCX | Halle Special Situations Fund LLC | 356,473 6.000% | 356,473 (New Position) | Filing History |